Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 5.68% is 34% below its 3-year average of 8.54%, near the low end of its 3-year range (1.89%–14.60%).
As of the fiscal period ended Wednesday, December 31, 2025. 23.20% below its 12-month average of 7.39%.
Reported quarterly debt to assets ratio; no daily interpolation. Q4 FY2025 (2025-12-31): 5.68%.
DEBT TO ASSETS RATIO
5.68%
DEBT TO ASSETS RATIO AVG TTM
7.39%
DEBT TO ASSETS RATIO AVG 3Y
8.54%
DEBT TO ASSETS RATIO AVG 5Y
N/A
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-23.20%
CURRENT VS 3Y AVG
-33.52%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11%
median of 522 covered companies
CURRENT VS SECTOR MEDIAN
+5305.69%
vs the sector median at left
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
Market Cap
$5.97M
Debt to Assets Ratio
5.68%
TTM Avg
7.39%
3Y Avg
8.54%
5Y Avg
N/A
Market Cap
$5.98M
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.23M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.55M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.54M
Debt to Assets Ratio
0.15%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.52M
Debt to Assets Ratio
0.07%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) | $5.97M | 5.68% | 7.39% | 8.54% | N/A |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $5.98M | 0.05% | N/A | N/A | N/A |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $6.23M | 0.00% | N/A | N/A | N/A |
| Femasys Inc. (FEMY)vs › | $6.25M | 0.39% | N/A | N/A | N/A |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.55M | 0.00% | N/A | N/A | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.54M | 0.15% | N/A | N/A | N/A |
| Biomerica, Inc. (BMRA)vs › | $6.40M | 0.28% | N/A | N/A | N/A |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.52M | 0.07% | N/A | N/A | N/A |
| Alzamend Neuro Inc (ALZN)vs › | $5.40M | 0.00% | N/A | N/A | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.36M | 0.42% | N/A | N/A | N/A |
Debt/Assets
5.7%
Debt/Equity
0.10
Current Ratio
2.35
Interest Coverage
-310.2x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2025-12-31 | 5.68% |
| 2025-06-30 | 1.89% |
| 2024-12-31 | 14.60% |
| 2024-06-30 | 5.41% |
| 2023-12-31 | 7.68% |
| 2023-06-30 | 11.72% |
| 2022-12-31 | 12.79% |
